Company intelligence / Profile preview

Keen Eye

Paris, Île-de-France, Francekeeneyemarketing.com ↗

Ownership: Private
Development stage: Other

Overview

Keen Eye has developed a GCLP-compliant AI web-based platform for digital image analysis in clinical trials. The technology enables efficient biomarker detection and quantification to support drug development and diagnostics. It has been validated through industry partnerships and adoption by CROs such as Iris Pharma for ophthalmology research. No direct clinical trial results since it’s a technology/service provider.

Therapeutic areas: OphthalmologyOncology
Modalities: Non-pharmacological therapy
Industry: Pathology

Partnerships

Iris Pharma

Beyond the preview

Go deeper on Keen Eye.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keen Eye.

Explore the full profile